In conclusion, we suggest that sunitinib leads to vascular dysfunction and hypertension via the mechanisms including insulin resistance- and VEGF/Pellino-1-mediated decrease in AKT/eNOS/NO signaling. The gene discussed is AKT1; the disease is Insulin resistance.